Progyny (NASDAQ:PGNY) COO Melissa Cummings Sells 1,879 Shares of Stock

Progyny, Inc. (NASDAQ:PGNY) COO Melissa Cummings sold 1,879 shares of the stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $28.00, for a total transaction of $52,612.00. Following the transaction, the chief operating officer owned 66,496 shares in the company, valued at approximately $1,861,888. This trade represents a 2.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Progyny Trading Down 2.1%

PGNY stock traded down $0.59 on Friday, hitting $26.86. The company had a trading volume of 919,547 shares, compared to its average volume of 1,253,538. Progyny, Inc. has a 12-month low of $16.10 and a 12-month high of $33.06. The stock’s 50-day simple moving average is $26.40 and its 200 day simple moving average is $25.46. The stock has a market cap of $2.06 billion, a price-to-earnings ratio of 29.20, a P/E/G ratio of 1.90 and a beta of 1.02.

Progyny (NASDAQ:PGNY) last posted its earnings results on Thursday, August 6th. The company reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. The business had revenue of $350.51 million during the quarter, compared to the consensus estimate of $349.05 million. Progyny had a net margin of 6.00% and a return on equity of 15.98%. The firm’s revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.19 EPS. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. Research analysts forecast that Progyny, Inc. will post 1.25 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Toth Financial Advisory Corp raised its holdings in Progyny by 21.3% in the 3rd quarter. Toth Financial Advisory Corp now owns 2,735 shares of the company’s stock worth $69,000 after purchasing an additional 480 shares during the period. WINTON GROUP Ltd lifted its position in Progyny by 266.7% during the second quarter. WINTON GROUP Ltd now owns 251,834 shares of the company’s stock valued at $7,260,000 after purchasing an additional 183,163 shares in the last quarter. Engineers Gate Manager LP lifted its position in Progyny by 5.6% during the second quarter. Engineers Gate Manager LP now owns 152,757 shares of the company’s stock valued at $4,404,000 after purchasing an additional 8,156 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new position in Progyny during the second quarter valued at $74,000. Finally, IFP Advisors Inc grew its holdings in Progyny by 376.0% during the second quarter. IFP Advisors Inc now owns 1,961 shares of the company’s stock valued at $57,000 after purchasing an additional 1,549 shares during the period. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on PGNY. BTIG Research lifted their price objective on Progyny from $30.00 to $40.00 and gave the stock a “buy” rating in a report on Friday, July 24th. Weiss Ratings raised Progyny from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. KeyCorp raised their target price on Progyny from $30.00 to $35.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. Canaccord Genuity Group set a $35.00 target price on Progyny in a research report on Friday, August 7th. Finally, Citigroup restated an “outperform” rating on shares of Progyny in a research note on Tuesday, September 8th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat, Progyny currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.36.

About Progyny

Progyny, Inc (NASDAQ: PGNY) is a fertility and family-building benefits company that helps employers provide reproductive health services to their employees. Its platform is designed to support individuals and families navigating fertility treatment, preservation, adoption, surrogacy and related family-building needs.

The company offers an integrated benefits solution that combines personalized care navigation with access to a network of fertility specialists and treatment providers. Progyny also provides pharmacy benefits through Progyny Rx, helping members obtain and manage medications commonly used in fertility treatments.

Progyny primarily serves employer-sponsored benefit programs in the United States.